Reaction Biology is a contract research organization (CRO) specializing in drug discovery services. The company provides a wide range of preclinical drug testing and integrated drug discovery solutions, primarily serving pharmaceutical and biotechnology companies. Operating in the highly competitive drug discovery market, Reaction Biology accelerates the drug development process by offering an extensive array of assays and services, including kinase, cell-based, biophysical, and epigenetic assays. The company's business model is fee-for-service, where clients pay for specific preclinical testing and research services. Revenue is generated through these service fees, which are structured based on the complexity and scope of the projects. Reaction Biology's unique value proposition lies in its Reaction Oncology Platform, which supports every step of cancer drug discovery from target research to lead optimization. This platform leverages a global network of strategic partners and scientific expertise to deliver high-quality data in a timely and collaborative manner. The company's mission is to provide excellent data and accelerate the journey to a lead drug candidate, ensuring effective treatments for patients.

Keywords: drug discovery, CRO, preclinical testing, oncology, kinase assays, cell-based assays, biophysical assays, epigenetic assays, pharmaceutical, biotechnology.